Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.75 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542459 | 0.93 | GRIA1 (0.71) | GRIA1GRIA4LMNANPY5RCA12 | |
| SCHEMBL7042049 | 0.86 | GRIA1 (1.00) | GRIA1GRIA4LMNANPY5RPPARA | |
| SCHEMBL7039391 | 0.86 | GRIA1 (1.00) | GRIA1GRIA4LMNANPY5RPPARA | |
| SCHEMBL7109326 | 0.86 | GRIA1 (1.00) | GRIA1GRIA4LMNANPY5RPPARA | |
| SCHEMBL18198023 | 0.84 | GRIA1 (0.62) | GRIA1GRIA4 | |
| SCHEMBL12232575 | 0.83 | GRIA1 (0.57) | GRIA1LMNAPPARACA1CA2 | |
| SCHEMBL4762362 | 0.80 | GRIA1 (0.46) | GRIA1LMNAPPARACA12CA1 | |
| SCHEMBL14654996 | 0.80 | GRIA1 (0.78) | GRIA1PPARACA12CA1CA2 | |
| SCHEMBL1726875 | 0.80 | GRIA1 (0.46) | GRIA1LMNAPPARACA12CA1 | |
| SCHEMBL24137992 | 0.79 | GRIA1 (0.62) | GRIA1GRIA4NPY5RCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | GRIA1 1537/4885GRIA4 2941/4885LMNA 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.